AU1639492A – Processes for the diastereoselective synthesis of nucleosides
– Google Patents
AU1639492A – Processes for the diastereoselective synthesis of nucleosides
– Google Patents
Processes for the diastereoselective synthesis of nucleosides
Info
Publication number
AU1639492A
AU1639492A
AU16394/92A
AU1639492A
AU1639492A
AU 1639492 A
AU1639492 A
AU 1639492A
AU 16394/92 A
AU16394/92 A
AU 16394/92A
AU 1639492 A
AU1639492 A
AU 1639492A
AU 1639492 A
AU1639492 A
AU 1639492A
Authority
AU
Australia
Prior art keywords
processes
nucleosides
diastereoselective synthesis
diastereoselective
synthesis
Prior art date
1991-05-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU16394/92A
Other versions
AU655973B2
(en
Inventor
Haolun Jin
Tarek Mansour
M. Arshad Siddiqui
Allan H.L. Tse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
Shire Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1991-05-21
Filing date
1992-05-20
Publication date
1992-11-26
Family has litigation
First worldwide family litigation filed
litigation
Critical
https://patents.darts-ip.com/?family=24825144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU1639492(A)
“Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
1992-05-20
Application filed by Shire Canada Inc
filed
Critical
Shire Canada Inc
1992-11-26
Publication of AU1639492A
publication
Critical
patent/AU1639492A/en
1995-01-19
Application granted
granted
Critical
1995-01-19
Publication of AU655973B2
publication
Critical
patent/AU655973B2/en
2008-04-10
Assigned to SHIRE CANADA INC.
reassignment
SHIRE CANADA INC.
Request to Amend Deed and Register
Assignors: BIOCHEM PHARMA INC.
2012-05-20
Anticipated expiration
legal-status
Critical
Status
Expired
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P31/12—Antivirals
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D317/34—Oxygen atoms
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
C07D327/04—Five-membered rings
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
C07D339/02—Five-membered rings
C07D339/06—Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
C07H19/06—Pyrimidine radicals
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
C07H19/16—Purine radicals
Abstract
The present invention relates to highly diastereoselective processes for production of cis-nucleosides and nucleoside analogues and derivatives in high optical purity and intermediates useful in those processes.
AU16394/92A
1991-05-21
1992-05-20
Processes for the diastereoselective synthesis of nucleosides
Expired
AU655973B2
(en)
Applications Claiming Priority (2)
Application Number
Priority Date
Filing Date
Title
US70337991A
1991-05-21
1991-05-21
US703379
1991-05-21
Publications (2)
Publication Number
Publication Date
AU1639492A
true
AU1639492A
(en)
1992-11-26
AU655973B2
AU655973B2
(en)
1995-01-19
Family
ID=24825144
Family Applications (4)
Application Number
Title
Priority Date
Filing Date
AU16395/92A
Ceased
AU668086B2
(en)
1991-05-21
1992-05-20
Processes for the diastereoselective synthesis of nucleosides
AU16913/92A
Abandoned
AU1691392A
(en)
1991-05-21
1992-05-20
Processes for the diastereoselective synthesis of nucleosides
AU16908/92A
Abandoned
AU1690892A
(en)
1991-05-21
1992-05-20
Processes for the diastereoselective synthesis of nucleosides
AU16394/92A
Expired
AU655973B2
(en)
1991-05-21
1992-05-20
Processes for the diastereoselective synthesis of nucleosides
Family Applications Before (3)
Application Number
Title
Priority Date
Filing Date
AU16395/92A
Ceased
AU668086B2
(en)
1991-05-21
1992-05-20
Processes for the diastereoselective synthesis of nucleosides
AU16913/92A
Abandoned
AU1691392A
(en)
1991-05-21
1992-05-20
Processes for the diastereoselective synthesis of nucleosides
AU16908/92A
Abandoned
AU1690892A
(en)
1991-05-21
1992-05-20
Processes for the diastereoselective synthesis of nucleosides
Country Status (34)
Country
Link
US
(5)
US5756706A
(en)
EP
(2)
EP0515157B1
(en)
JP
(3)
JP3229013B2
(en)
KR
(3)
KR0160144B1
(en)
CN
(6)
CN1035555C
(en)
AT
(2)
ATE157662T1
(en)
AU
(4)
AU668086B2
(en)
BG
(2)
BG61695B1
(en)
CA
(2)
CA2069024C
(en)
CZ
(3)
CZ284975B6
(en)
DE
(2)
DE69208144T2
(en)
DK
(2)
DK0515157T3
(en)
EE
(1)
EE03044B1
(en)
ES
(2)
ES2084937T3
(en)
FI
(3)
FI106377B
(en)
GR
(2)
GR3018941T3
(en)
GT
(1)
GT199800047A
(en)
HK
(2)
HK132196A
(en)
HU
(2)
HU223838B1
(en)
IE
(2)
IE921618A1
(en)
IL
(6)
IL101931A
(en)
MD
(1)
MD1155C2
(en)
MX
(2)
MX9202404A
(en)
NO
(2)
NO300593B1
(en)
NZ
(2)
NZ242818A
(en)
OA
(1)
OA10212A
(en)
PL
(3)
PL176026B1
(en)
RO
(1)
RO116812B1
(en)
RU
(4)
RU2163909C2
(en)
SG
(1)
SG43863A1
(en)
SK
(2)
SK279438B6
(en)
TW
(4)
TW467907B
(en)
WO
(2)
WO1992020669A1
(en)
ZA
(2)
ZA923641B
(en)
Cited By (1)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
AU668086B2
(en)
*
1991-05-21
1996-04-26
Shire Canada Inc.
Processes for the diastereoselective synthesis of nucleosides
Families Citing this family (108)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US6903224B2
(en)
1988-04-11
2005-06-07
Biochem Pharma Inc.
Substituted 1,3-oxathiolanes
US5684164A
(en)
1988-04-11
1997-11-04
Biochem Pharma Inc.
Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5466806A
(en)
*
1989-02-08
1995-11-14
Biochem Pharma Inc.
Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6350753B1
(en)
1988-04-11
2002-02-26
Biochem Pharma Inc.
2-Substituted-4-substituted-1,3-dioxolanes and use thereof
DE69233014T2
(en)
*
1989-02-08
2004-01-08
Biochem Pharma Inc., Laval
METHOD FOR THE PRODUCTION OF ANTIVIRAL SUBSTITUTED 1, 3-OXATHIOLANS
US5276151A
(en)
*
1990-02-01
1994-01-04
Emory University
Method of synthesis of 1,3-dioxolane nucleosides
US5204466A
(en)
*
1990-02-01
1993-04-20
Emory University
Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1
(en)
1990-02-01
2004-03-09
Emory University
Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5827727A
(en)
*
1990-02-01
1998-10-27
Emory University
Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5914331A
(en)
*
1990-02-01
1999-06-22
Emory University
Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5587480A
(en)
*
1990-11-13
1996-12-24
Biochem Pharma, Inc.
Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5925643A
(en)
*
1990-12-05
1999-07-20
Emory University
Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A
(en)
*
1990-12-05
1995-08-22
Emory University
Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1
(en)
1991-03-06
2004-11-02
Emory University
Therapeutic nucleosides
US5817667A
(en)
*
1991-04-17
1998-10-06
University Of Georgia Research Foudation
Compounds and methods for the treatment of cancer
GB9226879D0
(en)
*
1992-12-23
1993-02-17
Iaf Biochem Int
Anti-viral compounds
US6444656B1
(en)
1992-12-23
2002-09-03
Biochem Pharma, Inc.
Antiviral phosphonate nucleotides
US6005107A
(en)
1992-12-23
1999-12-21
Biochem Pharma, Inc.
Antiviral compounds
GB9226927D0
(en)
*
1992-12-24
1993-02-17
Iaf Biochem Int
Dideoxy nucleoside analogues
US5627160A
(en)
*
1993-05-25
1997-05-06
Yale University
L-2′,3′-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
TW374087B
(en)
*
1993-05-25
1999-11-11
Univ Yale
L-2′,3′-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
GB9311709D0
(en)
*
1993-06-07
1993-07-21
Iaf Biochem Int
Stereoselective synthesis of nucleoside analogues using bicycle intermediate
JPH09504785A
(en)
1993-09-10
1997-05-13
エモリー、ユニバーシティー
Nucleosides with anti-hepatitis B virus activity
US20020120130A1
(en)
1993-09-10
2002-08-29
Gilles Gosselin
2′ or 3′ -deoxy and 2′, 3′ -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A
(en)
*
1994-01-28
1996-12-24
Univ. Of Ga Research Foundation
L-nucleosides
IL113432A
(en)
*
1994-04-23
2000-11-21
Glaxo Group Ltd
Process for the diastereoselective synthesis of nucleoside analogues
GB9413724D0
(en)
1994-07-07
1994-08-24
Wellcome Found
Therapeutic nucleosides
US6448235B1
(en)
1994-07-11
2002-09-10
University Of Virginia Patent Foundation
Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1
(en)
1994-07-11
2003-02-04
University Of Virginia Patent Foundation
Method compositions for treating the inflammatory response
IL115156A
(en)
*
1994-09-06
2000-07-16
Univ Georgia
Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A
(en)
1995-01-27
1997-12-30
Emory University
Compositions containing 5-fluoro-2′,3′-didehydro-2′,3′-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1
(en)
1995-01-27
2002-05-21
Emory University
[5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A
(en)
*
1995-01-30
1998-09-15
Yale University
L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A
(en)
*
1995-03-16
1999-02-09
Yale University
Reducing toxicity of L-nucleosides with D-nucleosides
GB9506644D0
(en)
*
1995-03-31
1995-05-24
Wellcome Found
Preparation of nucleoside analogues
AU722214B2
(en)
1995-06-07
2000-07-27
Centre National De La Recherche Scientifique (Cnrs)
Nucleosides with anti-hepatitis B virus activity
KR100213932B1
(en)
*
1995-11-02
1999-08-02
김충환
Novel oligonucleoside derivatives and process for preparing the same
GB9600143D0
(en)
1996-01-05
1996-03-06
Wellcome Found
Therapeutic compounds
EP0799834A1
(en)
*
1996-04-04
1997-10-08
Novartis AG
Modified nucleotides
US6005097A
(en)
*
1996-06-14
1999-12-21
Vion Pharmaceuticals, Inc.
Processes for high-yield diastereoselective synthesis of dideoxynucleosides
US5753789A
(en)
*
1996-07-26
1998-05-19
Yale University
Oligonucleotides containing L-nucleosides
US6022876A
(en)
1996-11-15
2000-02-08
Yale University
L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
DE69819695D1
(en)
1997-02-13
2003-12-18
Glaxo Group Ltd
Benzimidazolderivate
EP0986375A2
(en)
1997-04-07
2000-03-22
Triangle Pharmaceuticals Inc.
Use of mkc-442 in combination with other antiviral agents
BR9810745A
(en)
1997-06-10
2001-03-13
Glaxo Group Ltd
Benzimidazole derivatives
CA2297076A1
(en)
1997-07-30
1999-02-11
The Regents Of The University Of Michigan
Lyxofuranosyl benzimidazoles as antiviral agents
US20030220234A1
(en)
*
1998-11-02
2003-11-27
Selvaraj Naicker
Deuterated cyclosporine analogs and their use as immunodulating agents
YU44900A
(en)
1998-01-31
2003-01-31
Glaxo Group Limited
2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2340214C
(en)
1998-08-12
2007-10-30
Triangle Pharmaceuticals, Inc.
Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1
(en)
1998-10-09
2005-12-27
Gilead Sciences, Inc.
Non-homogeneous systems for the resolution of enantiomeric mixtures
MXPA01006425A
(en)
1998-12-23
2002-06-04
Iaf Biochem Int
Antiviral nucleoside analogues.
US7635690B2
(en)
1999-01-22
2009-12-22
Emory University
HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7115584B2
(en)
1999-01-22
2006-10-03
Emory University
HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US6232297B1
(en)
1999-02-01
2001-05-15
University Of Virginia Patent Foundation
Methods and compositions for treating inflammatory response
US7378400B2
(en)
*
1999-02-01
2008-05-27
University Of Virginia Patent Foundation
Method to reduce an inflammatory response from arthritis
US7427606B2
(en)
*
1999-02-01
2008-09-23
University Of Virginia Patent Foundation
Method to reduce inflammatory response in transplanted tissue
YU25500A
(en)
1999-05-11
2003-08-29
Pfizer Products Inc.
Process for the synthesis of nucleosite analogues
US6322771B1
(en)
1999-06-18
2001-11-27
University Of Virginia Patent Foundation
Induction of pharmacological stress with adenosine receptor agonists
ATE269081T1
(en)
1999-09-24
2004-07-15
Shire Biochem Inc
DIOXOLANE NUCLEOSIDE ANALOGUES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS
AU1262001A
(en)
1999-11-04
2001-05-14
Biochem Pharma Inc.
Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
US6436948B1
(en)
2000-03-03
2002-08-20
University Of Georgia Research Foundation Inc.
Method for the treatment of psoriasis and genital warts
CA2308559C
(en)
*
2000-05-16
2005-07-26
Brantford Chemicals Inc.
1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
EP1903041B1
(en)
2001-03-01
2015-02-18
AbbVie Inc.
Polymorphic and other crystalline forms of cis-FTC
US6600044B2
(en)
2001-06-18
2003-07-29
Brantford Chemicals Inc.
Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
WO2003029264A2
(en)
*
2001-10-01
2003-04-10
University Of Virginia Patent Foundation
2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
NZ531944A
(en)
2001-10-19
2006-03-31
Isotechnika Inc
Synthesis of cyclosporin analogs
ITMI20012317A1
(en)
*
2001-11-06
2003-05-06
Recordati Ind Chimica E Farma
DIASTEREOSELECTIVE PROCESS FOR THE PREPARATION OF THE ANTIVIRAL AGENT4-AMINO-1- (2R-IDROSSIMETIL- / 1,3 / OSSATIOLAN-5S-I1) -1H-PIRIMIDIN-2-ONE
KR20040101991A
(en)
*
2001-12-14
2004-12-03
파마셋, 리미티드
Preparation of intermediates useful in the synthesis of antiviral nucleosides
US20050085638A1
(en)
*
2002-01-25
2005-04-21
Shire Biochem Inc
Process for producing dioxolane nucleoside analogues
US7365173B2
(en)
*
2002-02-04
2008-04-29
American National Red Cross
Method for the production of pure virally inactivated butyrylcholinesterase
AU2003294212B2
(en)
2002-08-06
2010-01-07
Pharmasset Inc.
Processes for preparing 1,3-dioxolane nucleosides
SI1583542T1
(en)
*
2003-01-14
2008-12-31
Gilead Sciences Inc
Compositions and methods for combination antiviral therapy
ITMI20030578A1
(en)
2003-03-24
2004-09-25
Clariant Lsm Italia Spa
PROCESS AND INTERMEDIATES FOR THE PREPARATION OF EMTRICITABINE
CN101044122A
(en)
2004-02-03
2007-09-26
埃莫里大学
Methods to manufacture 1,3-dioxolane nucleosides
WO2006028618A1
(en)
*
2004-08-02
2006-03-16
University Of Virginia Patent Foundation
2-polycyclic propynyl adenosine analogs with modified 5′-ribose groups having a2a agonist activity
AU2005267706B2
(en)
*
2004-08-02
2011-12-08
University Of Virginia Patent Foundation
2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
US7442687B2
(en)
*
2004-08-02
2008-10-28
The University Of Virginia Patent Foundation
2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7837651B2
(en)
*
2004-08-31
2010-11-23
Ethicon Endo-Surgery, Inc.
Infusion pump
US7250416B2
(en)
2005-03-11
2007-07-31
Supergen, Inc.
Azacytosine analogs and derivatives
TWI375560B
(en)
2005-06-13
2012-11-01
Gilead Sciences Inc
Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B
(en)
2005-06-13
2015-02-01
Bristol Myers Squibb & Gilead Sciences Llc
Unitary pharmaceutical dosage form
US7700567B2
(en)
2005-09-29
2010-04-20
Supergen, Inc.
Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007077505A2
(en)
*
2005-12-30
2007-07-12
Ranbaxy Laboratories Limited
Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof
US8178509B2
(en)
*
2006-02-10
2012-05-15
University Of Virginia Patent Foundation
Method to treat sickle cell disease
US8188063B2
(en)
*
2006-06-19
2012-05-29
University Of Virginia Patent Foundation
Use of adenosine A2A modulators to treat spinal cord injury
CA2667891A1
(en)
*
2006-10-30
2008-05-08
Lupin Limited
An improved process for the manufacture of lamivudine
CA2700267A1
(en)
2007-09-26
2009-04-02
Clavis Pharma Asa
Azacytidine analogues and uses thereof
US20100311970A1
(en)
*
2007-11-29
2010-12-09
Ranbaxy Laboratories Limited
Process for the preparation of substituted 1,3-oxathiolanes
WO2009069012A1
(en)
*
2007-11-29
2009-06-04
Ranbaxy Laboratories Limited
Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine
US8350030B2
(en)
2007-12-07
2013-01-08
Matrix Laboratories Limited
Process for producing 5-fluoro-1-(2R, 5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
US8058259B2
(en)
*
2007-12-20
2011-11-15
University Of Virginia Patent Foundation
Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
SG10201609006WA
(en)
2008-05-02
2016-12-29
Gilead Sciences Inc
The use of solid carrier particles to improve the processability of a pharmaceutical agent
WO2010082128A1
(en)
2009-01-19
2010-07-22
Aurobindo Pharma Limited
Process for the preparation of cis-nucleoside derivative
HUE025822T2
(en)
2009-02-06
2016-04-28
Gilead Sciences Inc
Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir
EP2521729A4
(en)
*
2010-01-08
2013-07-31
Hetero Research Foundation
Improved process for nucleosides
CA2787691C
(en)
2010-01-27
2018-07-17
Glaxosmithkline Llc
Combinations for use in the inhibition of hiv-1
US20120295930A1
(en)
*
2010-02-03
2012-11-22
Shankar Rama
Novel process for the preparation of cis-nucleoside derivative
WO2011107920A1
(en)
2010-03-04
2011-09-09
Ranbaxy Laboratories Limited
A process for stereoselective synthesis of 5-fluoro-1-(2r,5s)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
EP2377862A1
(en)
2010-03-29
2011-10-19
Esteve Química, S.A.
Process for obtaining emtricitabine
WO2011141805A2
(en)
2010-05-14
2011-11-17
Lupin Limited
An improved process for the manufacture of lamivudine
WO2012062835A1
(en)
2010-11-12
2012-05-18
Glaxo Wellcome Manufacturing Pte Ltd
Novel pharmaceutical compositions
US20130296562A1
(en)
2011-08-05
2013-11-07
Lupin Limited
Stereoselective process for preparation of 1,3-oxathiolane nucleosides
US9381207B2
(en)
2011-08-30
2016-07-05
Astex Pharmaceuticals, Inc.
Drug formulations
CN103242243B
(en)
*
2013-01-08
2015-08-19
北京大学
A kind of base triacetin ether-ether molecule, its chemical synthesis process and the application in field of gene thereof
CN103288806A
(en)
*
2013-07-02
2013-09-11
山东大学
Synthesis method of troxacitabine
KR20180024010A
(en)
2015-07-02
2018-03-07
오쓰까 세이야꾸 가부시키가이샤
The lyophilized pharmaceutical composition
CN105037340B
(en)
*
2015-07-14
2018-08-10
福建广生堂药业股份有限公司
A kind of preparation method of lamivudine key intermediate chiral isomer impurity
JP2020529409A
(en)
2017-08-03
2020-10-08
大塚製薬株式会社
Drug compounds and their purification methods
Family Cites Families (29)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
FR1445013A
(en)
*
1964-07-09
1966-07-08
Thomae Gmbh Dr K
Process for making new dioxolano-2-carboxylic acids
US4383114A
(en)
*
1977-02-09
1983-05-10
Regents Of The University Of Minnesota
Adenosine deaminase resistant antiviral purine arabinonucleosides
US4231945A
(en)
*
1978-11-08
1980-11-04
Schering Corporation
S-5-(Azidomethyl or aminomethyl)-2-lower-alkoxytetrahydrofurans
US4479942A
(en)
*
1981-08-10
1984-10-30
Fujisawa Pharmaceutical Co., Ltd.
Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof
US4855304A
(en)
*
1985-01-10
1989-08-08
Repligen Corporation
Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
DK363987A
(en)
*
1986-08-08
1988-02-09
Hoffmann La Roche
pyrimidine
GB8621268D0
(en)
*
1986-09-03
1986-10-08
Univ Strathclyde
Separation of substances
US4997818A
(en)
*
1987-09-21
1991-03-05
The University Hospital
Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas
SE8704298D0
(en)
*
1987-11-03
1987-11-03
Astra Ab
COMPOUNDS FOR USE IN THERAPY
US4997926A
(en)
*
1987-11-18
1991-03-05
Scripps Clinic And Research Foundation
Deaminase-stable anti-retroviral 2-halo-2′,3′-dideoxy
JPH022349A
(en)
*
1988-02-17
1990-01-08
Takeda Chem Ind Ltd
Pyrimidine analogue-tolerated gene dna and use thereof
US5047407A
(en)
*
1989-02-08
1991-09-10
Iaf Biochem International, Inc.
2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A
(en)
*
1988-04-11
1991-09-25
Iaf Biochem Int
1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
GB8815265D0
(en)
*
1988-06-27
1988-08-03
Wellcome Found
Therapeutic nucleosides
DE3823127A1
(en)
*
1988-07-08
1990-01-11
Rheinische Braunkohlenw Ag
DEVICE AND METHOD FOR PURIFYING WASTE WATER
US4987224A
(en)
*
1988-08-02
1991-01-22
University Of Georgia Research Foundation, Inc.
Method of preparation of 2′,3′-dideoxynucleosides
DE3827134A1
(en)
*
1988-08-10
1990-03-15
Bayer Ag
SUBSTITUTED TRIAZOLYL OR IMIDAZOLYL-HYDROXYALKYLDIOXOLANE, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MICROBICIDES, OXIRANYLDIOXOLANES, DIOXOLANYLKETONE, OXIRANYLKETONE AND (ALPHA) -HALOGENICENETHENO ZERO DETECTED
US5075225A
(en)
*
1989-04-06
1991-12-24
The Texas A&M University System
Process for the enzymatic synthesis of nucleosides
NZ233197A
(en)
*
1989-04-13
1991-11-26
Richard Thomas Walker
Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
IE902574A1
(en)
*
1989-07-17
1991-02-27
Univ Birmingham
Antiviral pyrimidine nucleosides
IE904378A1
(en)
*
1989-12-20
1991-07-03
Abbott Lab
Analogs of oxetanyl purines and pyrimidines
US5204466A
(en)
*
1990-02-01
1993-04-20
Emory University
Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0
(en)
*
1990-05-02
1990-06-27
Glaxo Group Ltd
Chemical compounds
GB9014090D0
(en)
*
1990-06-25
1990-08-15
Zaadunie Bv
Improvements in or relating to organic compounds
WO1992010496A1
(en)
*
1990-12-05
1992-06-25
University Of Georgia Research Foundation, Inc.
ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
IL100965A
(en)
*
1991-02-22
1999-12-31
Univ Emory
2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
WO1992018517A1
(en)
*
1991-04-17
1992-10-29
Yale University
Method of treating or preventing hepatitis b virus
GB9109506D0
(en)
*
1991-05-02
1991-06-26
Wellcome Found
Therapeutic nucleosides
ZA923641B
(en)
*
1991-05-21
1993-02-24
Iaf Biochem Int
Processes for the diastereoselective synthesis of nucleosides
1992
1992-05-19
ZA
ZA923641A
patent/ZA923641B/en
unknown
1992-05-19
ZA
ZA923640A
patent/ZA923640B/en
unknown
1992-05-20
RU
RU96119766/04A
patent/RU2163909C2/en
not_active
IP Right Cessation
1992-05-20
AU
AU16395/92A
patent/AU668086B2/en
not_active
Ceased
1992-05-20
NO
NO921989A
patent/NO300593B1/en
unknown
1992-05-20
IL
IL10193192A
patent/IL101931A/en
not_active
IP Right Cessation
1992-05-20
PL
PL92309052A
patent/PL176026B1/en
unknown
1992-05-20
IL
IL11610992A
patent/IL116109A/en
not_active
IP Right Cessation
1992-05-20
MD
MD95-0172A
patent/MD1155C2/en
unknown
1992-05-20
KR
KR1019920008507A
patent/KR0160144B1/en
not_active
IP Right Cessation
1992-05-20
IL
IL101932A
patent/IL101932A/en
not_active
IP Right Cessation
1992-05-20
DK
DK92304552.0T
patent/DK0515157T3/en
active
1992-05-20
CZ
CZ962224A
patent/CZ284975B6/en
not_active
IP Right Cessation
1992-05-20
EP
EP92304552A
patent/EP0515157B1/en
not_active
Expired – Lifetime
1992-05-20
NO
NO921988A
patent/NO301010B1/en
not_active
IP Right Cessation
1992-05-20
RU
RU99115480/04A
patent/RU2223960C2/en
active
1992-05-20
PL
PL92301340A
patent/PL170869B1/en
unknown
1992-05-20
IL
IL116176A
patent/IL116176A/en
not_active
IP Right Cessation
1992-05-20
PL
PL92301339A
patent/PL168910B1/en
not_active
IP Right Cessation
1992-05-20
KR
KR1019920008694A
patent/KR100232012B1/en
not_active
IP Right Cessation
1992-05-20
RO
RO93-01554A
patent/RO116812B1/en
unknown
1992-05-20
SK
SK1293-93A
patent/SK279438B6/en
not_active
IP Right Cessation
1992-05-20
DK
DK92304551.2T
patent/DK0515156T3/en
active
1992-05-20
SK
SK1294-93A
patent/SK281954B6/en
not_active
IP Right Cessation
1992-05-20
CA
CA002069024A
patent/CA2069024C/en
not_active
Expired – Fee Related
1992-05-20
WO
PCT/CA1992/000211
patent/WO1992020669A1/en
active
IP Right Grant
1992-05-20
NZ
NZ242818A
patent/NZ242818A/en
not_active
IP Right Cessation
1992-05-20
AU
AU16913/92A
patent/AU1691392A/en
not_active
Abandoned
1992-05-20
HU
HU9303296A
patent/HU223838B1/en
not_active
IP Right Cessation
1992-05-20
ES
ES92304551T
patent/ES2084937T3/en
not_active
Expired – Lifetime
1992-05-20
ES
ES92304552T
patent/ES2104832T3/en
not_active
Expired – Lifetime
1992-05-20
HU
HU9303297A
patent/HU221850B1/en
active
IP Right Grant
1992-05-20
CZ
CZ932492A
patent/CZ285220B6/en
not_active
IP Right Cessation
1992-05-20
NZ
NZ242817A
patent/NZ242817A/en
not_active
IP Right Cessation
1992-05-20
AT
AT92304552T
patent/ATE157662T1/en
active
1992-05-20
RU
RU93058362A
patent/RU2140925C1/en
active
1992-05-20
DE
DE69208144T
patent/DE69208144T2/en
not_active
Expired – Fee Related
1992-05-20
CA
CA002069063A
patent/CA2069063C/en
not_active
Expired – Lifetime
1992-05-20
US
US08/142,389
patent/US5756706A/en
not_active
Expired – Fee Related
1992-05-20
RU
RU93058554A
patent/RU2105009C1/en
not_active
IP Right Cessation
1992-05-20
SG
SG1996003228A
patent/SG43863A1/en
unknown
1992-05-20
AU
AU16908/92A
patent/AU1690892A/en
not_active
Abandoned
1992-05-20
DE
DE69221936T
patent/DE69221936T2/en
not_active
Expired – Lifetime
1992-05-20
EP
EP92304551A
patent/EP0515156B1/en
not_active
Expired – Lifetime
1992-05-20
WO
PCT/CA1992/000209
patent/WO1992020696A1/en
active
IP Right Grant
1992-05-20
AT
AT92304551T
patent/ATE133958T1/en
not_active
IP Right Cessation
1992-05-20
AU
AU16394/92A
patent/AU655973B2/en
not_active
Expired
1992-05-20
CZ
CZ932493A
patent/CZ280857B6/en
not_active
IP Right Cessation
1992-05-21
JP
JP12915592A
patent/JP3229013B2/en
not_active
Expired – Lifetime
1992-05-21
MX
MX9202404A
patent/MX9202404A/en
unknown
1992-05-21
US
US08/142,387
patent/US5696254A/en
not_active
Expired – Lifetime
1992-05-21
CN
CN92103924A
patent/CN1035555C/en
not_active
Expired – Fee Related
1992-05-21
MX
MX9202395A
patent/MX9202395A/en
unknown
1992-05-21
CN
CN92103921A
patent/CN1038591C/en
not_active
Expired – Lifetime
1992-05-21
JP
JP12916392A
patent/JP3330972B2/en
not_active
Expired – Fee Related
1992-06-02
TW
TW088109374A
patent/TW467907B/en
not_active
IP Right Cessation
1992-06-02
TW
TW081104323A
patent/TW366350B/en
not_active
IP Right Cessation
1992-06-02
TW
TW081104321A
patent/TW366349B/en
not_active
IP Right Cessation
1992-06-02
TW
TW088109433A
patent/TWI245046B/en
not_active
IP Right Cessation
1992-07-01
IE
IE161892A
patent/IE921618A1/en
not_active
IP Right Cessation
1992-07-01
IE
IE921619A
patent/IE76741B1/en
not_active
IP Right Cessation
1993
1993-11-19
FI
FI935151A
patent/FI106377B/en
not_active
IP Right Cessation
1993-11-19
OA
OA60440A
patent/OA10212A/en
unknown
1993-11-19
FI
FI935150A
patent/FI109025B/en
active
1993-12-20
BG
BG98310A
patent/BG61695B1/en
unknown
1993-12-20
BG
BG98311A
patent/BG61696B1/en
unknown
1994
1994-10-20
EE
EE9400283A
patent/EE03044B1/en
unknown
1995
1995-03-10
CN
CN95102412A
patent/CN1050603C/en
not_active
Expired – Lifetime
1995-06-05
US
US08/464,960
patent/US5744596A/en
not_active
Expired – Fee Related
1995-06-05
US
US08/464,317
patent/US5693787A/en
not_active
Expired – Lifetime
1995-06-05
US
US08/460,856
patent/US5663320A/en
not_active
Expired – Lifetime
1995-11-23
IL
IL11610995A
patent/IL116109A0/en
unknown
1995-11-28
IL
IL11617695A
patent/IL116176A0/en
unknown
1996
1996-02-08
GR
GR960400299T
patent/GR3018941T3/en
unknown
1996-07-18
HK
HK132196A
patent/HK132196A/en
not_active
IP Right Cessation
1997
1997-09-04
GR
GR970400204T
patent/GR3024617T3/en
unknown
1998
1998-02-24
HK
HK98101405A
patent/HK1002431A1/en
not_active
IP Right Cessation
1998-03-04
GT
GT199800047A
patent/GT199800047A/en
unknown
1998-12-03
CN
CN98122384A
patent/CN1097049C/en
not_active
Expired – Lifetime
1998-12-03
CN
CN98122383A
patent/CN1109030C/en
not_active
Expired – Lifetime
1998-12-03
CN
CN98122385A
patent/CN1083450C/en
not_active
Expired – Lifetime
1999
1999-07-12
KR
KR1019990027976A
patent/KR100242921B1/en
not_active
IP Right Cessation
2000
2000-08-29
FI
FI20001900A
patent/FI20001900A/en
unknown
2001
2001-05-07
JP
JP2001136217A
patent/JP3704055B2/en
not_active
Expired – Lifetime
Cited By (1)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
AU668086B2
(en)
*
1991-05-21
1996-04-26
Shire Canada Inc.
Processes for the diastereoselective synthesis of nucleosides
Also Published As
Publication number
Publication date
IE921619A1
(en)
1992-12-02
JP3229013B2
(en)
2001-11-12
HUT67471A
(en)
1995-04-28
US5696254A
(en)
1997-12-09
WO1992020669A1
(en)
1992-11-26
SK279438B6
(en)
1998-11-04
PL168910B1
(en)
1996-05-31
HU9303296D0
(en)
1994-03-28
CN1097049C
(en)
2002-12-25
ATE133958T1
(en)
1996-02-15
ES2104832T3
(en)
1997-10-16
JP2001354667A
(en)
2001-12-25
FI20001900A
(en)
2000-08-29
KR100242921B1
(en)
2000-03-15
PL170869B1
(en)
1997-01-31
US5693787A
(en)
1997-12-02
EP0515157A1
(en)
1992-11-25
CZ280857B6
(en)
1996-04-17
IL116176A
(en)
1998-02-08
ZA923641B
(en)
1993-02-24
DE69208144D1
(en)
1996-03-21
DE69208144T2
(en)
1996-09-05
ATE157662T1
(en)
1997-09-15
GT199800047A
(en)
1999-08-26
MX9202404A
(en)
1993-08-31
WO1992020696A1
(en)
1992-11-26
FI106377B
(en)
2001-01-31
DK0515157T3
(en)
1997-09-29
CN1038591C
(en)
1998-06-03
IE76741B1
(en)
1997-11-05
NO921989D0
(en)
1992-05-20
IL116109A0
(en)
1996-01-31
CA2069024A1
(en)
1992-11-22
CN1229080A
(en)
1999-09-22
IL101931A0
(en)
1992-12-30
BG98311A
(en)
1994-08-30
RO116812B1
(en)
2001-06-29
NO921988L
(en)
1992-11-23
KR100232012B1
(en)
1999-12-01
CN1050603C
(en)
2000-03-22
TWI245046B
(en)
2005-12-11
US5663320A
(en)
1997-09-02
RU2140925C1
(en)
1999-11-10
NZ242818A
(en)
1994-04-27
CZ249393A3
(en)
1994-04-13
KR920021576A
(en)
1992-12-18
FI935151A0
(en)
1993-11-19
SK129393A3
(en)
1994-07-06
ES2084937T3
(en)
1996-05-16
FI935151A
(en)
1993-11-19
SK281954B6
(en)
2001-09-11
JP3704055B2
(en)
2005-10-05
HU9303297D0
(en)
1994-03-28
CN1109030C
(en)
2003-05-21
BG61695B1
(en)
1998-03-31
KR0160144B1
(en)
1998-11-16
JP3330972B2
(en)
2002-10-07
IL116109A
(en)
1998-12-27
TW366350B
(en)
1999-08-11
CZ222496A3
(en)
1999-04-14
FI935150A
(en)
1993-11-19
EE03044B1
(en)
1997-10-15
CN1083450C
(en)
2002-04-24
KR920021575A
(en)
1992-12-18
CZ284975B6
(en)
1999-04-14
CN1229079A
(en)
1999-09-22
EP0515157B1
(en)
1997-09-03
BG98310A
(en)
1994-01-03
DE69221936T2
(en)
1998-01-02
NO921989L
(en)
1992-11-23
NZ242817A
(en)
1995-03-28
MD1155B2
(en)
1999-02-28
HU221850B1
(en)
2003-02-28
TW366349B
(en)
1999-08-11
TW467907B
(en)
2001-12-11
CA2069063A1
(en)
1992-11-22
CN1067654A
(en)
1993-01-06
CN1067245A
(en)
1992-12-23
CN1116204A
(en)
1996-02-07
MX9202395A
(en)
1993-02-01
AU655973B2
(en)
1995-01-19
HU223838B1
(en)
2005-02-28
RU2223960C2
(en)
2004-02-20
AU1691392A
(en)
1992-12-30
MD950172A
(en)
1996-08-30
CN1035555C
(en)
1997-08-06
FI109025B
(en)
2002-05-15
CZ249293A3
(en)
1994-03-16
AU1639592A
(en)
1992-11-26
SK129493A3
(en)
1994-11-09
GR3018941T3
(en)
1996-05-31
DK0515156T3
(en)
1996-06-17
MD1155C2
(en)
1999-10-31
PL176026B1
(en)
1999-03-31
RU2163909C2
(en)
2001-03-10
JPH05186463A
(en)
1993-07-27
DE69221936D1
(en)
1997-10-09
IL101932A0
(en)
1992-12-30
FI935150A0
(en)
1993-11-19
ZA923640B
(en)
1993-02-24
NO301010B1
(en)
1997-09-01
BG61696B1
(en)
1998-03-31
NO300593B1
(en)
1997-06-23
US5756706A
(en)
1998-05-26
EP0515156B1
(en)
1996-02-07
CZ285220B6
(en)
1999-06-16
CA2069024C
(en)
1997-09-23
HK1002431A1
(en)
1998-08-21
JPH05186465A
(en)
1993-07-27
IL101932A
(en)
1997-04-15
SG43863A1
(en)
1997-11-14
US5744596A
(en)
1998-04-28
AU1690892A
(en)
1992-12-30
IE921618A1
(en)
1992-12-02
HK132196A
(en)
1996-07-26
RU2105009C1
(en)
1998-02-20
IL116176A0
(en)
1996-01-31
NO921988D0
(en)
1992-05-20
CN1229078A
(en)
1999-09-22
AU668086B2
(en)
1996-04-26
EP0515156A1
(en)
1992-11-25
CA2069063C
(en)
1997-07-15
GR3024617T3
(en)
1997-12-31
HUT67726A
(en)
1995-04-28
OA10212A
(en)
1997-10-07
IL101931A
(en)
1996-12-05
Similar Documents
Publication
Publication Date
Title
AU1639592A
(en)
1992-11-26
Processes for the diastereoselective synthesis of nucleosides
None